NHS Intelligence · Analysis and reporting
Place NHS activity in the context of access decisions.
Explore published medicine activity over time alongside positive decisions from the relevant UK HTA body.
Choose the nation, source, organisation level, presentation, measure and period relevant to your question. Review the resulting series and export your selected analysis for further discussion.
Choose the timeline your question needs
Select the nation, published source, organisation level, medicine presentation, measure and period. Review how recorded activity changes within that scope rather than combining unlike measures or reporting periods.
Place access decisions on the timeline
Positive decisions from the relevant UK HTA body - NICE for England, SMC for Scotland - appear as historical markers. They help frame questions about the sequence of events.
Decision markers provide historical context; they do not establish that an HTA decision caused a change in activity.

Carry the selected series into discussion
Export the selected analysis for further examination, with the source, organisation level, presentation and reporting period attached.
When to use NHS Analytics instead
Use NHS Intelligence to investigate when recorded activity changed in relation to published decision dates. Use NHS Analytics to examine where activity and cost are concentrated across organisations. Neither establishes local pathways, unpublished access decisions or patient-level uptake.
Sources behind these findings
NHS Analytics
England and Scotland kept separate with nation-specific measures
Source: Synapptiq application · Reviewed 2026-10-27 · Review due 2027-10-27
Shown in context - no causal claim
Positive UK HTA decisions marked on NHS Intelligence timeline (NICE England, SMC Scotland)
Source: Synapptiq application · Reviewed 2026-10-27 · Review due 2027-10-27
Continue your evidence review
Decision focus: Examine published NHS activity and cost
Where is it used, how much, and when did that change?
For Launch and commercial teamsConnected capabilities
Worked example
Alirocumab: examining NICE TA3935 of 9 capabilities
